Perioperative intravenous dexamethasone reduces postoperative pain, opioid consumption, and nausea/vomiting after primary total joint arthroplasty. (1A)

There is insufficient evidence on whether intravenous dexa_x005fmethasone increases the risk of complications after primary total joint arthroplasty,including periprosthetic joint infection and wound healing. (1B)

There is limited evidence to determine if there is a difference between high dose and low dose intravenous dexamethasone with regard to postoperative pain, opioid consumption, nausea/vomit_x005fing, or complications after primary total joint arthroplasty.（Strength of Recommendation：Limited）

Multiple doses of perioperative intravenous dexamethasone lead to reduced pain, opioid consumption, and nausea/ vomiting compared to a single dose of perioperative intravenous dexamethasone.（Strength of ecommendation：Strong）

The attending physicians of patients should perform a comprehensive assessment of the patient's preoperative blood glucose levels and diabetes‐associated complications that can affect the surgical prognosis. (1B)

Medical staff who are directly associated with the patient during the perioperative period, including attending physicians, endocrinologists, anaesthesiologists and nurses should communicate with each other at least once during the management of perioperative blood glucose and clarify their respective duties at different stages. (1B) If possible, it is suggested that a targeted perioperative management program for patients be developed facilitate effective coordination and cooperation. (2B)